Many cancer patients are treated with chemotherapy that unspecifically targets all proliferative cells leading to severe side effects and a high relapse rate. The high relapse rate is a result of the inefficiency of conventional therapy to eradicate the cancer stem cells (CSC) that are believed to drive the disease and to be resistant to chemotherapy. Our goal is to understand the mechanisms driving cancer by functionally and molecularly identifying the cancer stem cells that are resistant to chemotherapy. In addition, we aim to develop a small molecule platform for drug profiling in order to find the most optimal drug combination for each patient targeting all cancer cells including the cancer stem cells. Our hope is that our results will improve survival and patient suffering during treatment, which will also have a positive effect on the socio-economic level.
Recent research outputs
View All (9)